Stoke Therapeutics, Inc.
Every calculator, already run for STOK
Open the full toolkit →You have the numbers on STOK. Get the argument.
A written report on which of these readings actually decide the outcome for Stoke Therapeutics, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
14 analysts covering STOKAnalyst Price Target Disagreement for Stoke Therapeutics, Inc.
Wall Street's bull case implies +114% from the current price; the bear case implies +25%. A 89% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for STOK
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Stoke Therapeutics, Inc.
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase 3 clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of…
STOK — frequently asked
Is STOK a buy right now?
Wall Street's consensus rating on Stoke Therapeutics, Inc. is none across 14 analysts, with a mean price target of $46.46 (+66% vs. the current $28.05). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is STOK's next earnings date?
Stoke Therapeutics, Inc. is next scheduled to report earnings around Nov 3, 2026. A full STOK research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Stoke Therapeutics, Inc.?
Analysts covering Stoke Therapeutics, Inc. (STOK) range from a bear-case target of $35.00 to a bull-case high of $60.00, with a mean consensus target of $46.46 across 13 analysts. The spread of $25.00 (89% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Stoke Therapeutics, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Stoke Therapeutics, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full STOK research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Stoke Therapeutics, Inc., in minutes. 3 free reports included with every account — no credit card required.